November 20, 2026
Andamertinib Benzoate Capsules (安比锐®) Companion Diagnostic Kit Receives NMPA Approval

On November 20, 2026, Guangzhou Burning Rock Dx Co., Ltd. (NASDAQ: BNR, Burning Rock) and Beijing Avistone Biotechnology Co., Ltd. (Avistone) jointly announced that the companion diagnostic kit for Andamertinib Benzoate Capsules (安比锐®, Andamertinib), developed through their collaboration, has received approval from China’s National Medical Products Administration (NMPA). The kit is approved for detecting EGFR exon 20 insertion (exon20ins) mutations in patients with non-small cell lung cancer (NSCLC), supporting the identification of eligible patients and informed treatment decisions.


Andamertinib, an EGFR exon 20 insertion (exon20ins) inhibitor independently developed by Avistone Pharmaceutical (Ningbo) Co., Ltd. (Ningbo Avistone), a wholly owned subsidiary of Avistone, received conditional approval from the NMPA on April 30, 2026. It is indicated for adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or following platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy, and who have been confirmed by testing to have an exon 20 insertion mutation in EGFR.


On November 14, 2026, Andamertinib was included for the first time in China’s 2026 National Reimbursement Drug List (NRDL), which will take effect on January 1, 2027, potentially improving access to and affordability of this innovative treatment.

Learn More
January 26, 2026
Milestone in Precision Oncology! Burning Rock Dx’s Breast Cancer NGS CDx Kit Enters the CMDE Priority Review Channel
Learn More
January 06, 2026
Burning Rock’s Liquid Biopsy Technology Granted U.S. Patent, Accelerating Global Layout in Precision Diagnosis
Learn More
December 18, 2025
From Accreditation to Excellence: Webinar Highlights on CAP, CLIA, and Quality Systems in Clinical Laboratories
Learn More
September 24, 2025
Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
Learn More
July 24, 2025
Burning Rock Dx Laboratory Receives Accreditation from College of American Pathologists
Learn More
October 11, 2024
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
Learn More
August 21, 2024
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
Learn More
August 21, 2024
Burning Rock Announces the Launch of China’s First Prospective Pan-Cancer Multi-omics Early Detection Study
Learn More
October 31, 2023
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics
Learn More
1 2 3 4
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."